We are monitoring the impact of COVID-19 on Europe Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 794
Share on
Share on

Europe Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends & Forecast (2021 to 2026)

Pulished: April, 2021
ID: 794
Pages: 145

Europe Melanoma Therapeutics Market Size (2021 to 2026)

The size of the Melanoma Therapeutics Market in Europe is predicted to be USD 1.77 billion by 2026 from USD 0.84 billion in 2021, growing at a CAGR of 16.2% during the forecast period. 

The market for melanoma therapeutics is growing at a significant rate due to the increasing prevalence of melanoma and improving healthcare facilities. According to the Skin Cancer Foundation, an estimated total of 73,900 new cases of melanoma diagnosed is expected in 2018. In addition, with an expected death toll of 9,999 cases, melanoma would account for the majority of skin cancer deaths in 2018.

Factors which play a key role in the development of the melanoma therapeutics market in Europe include increasing prevalence of melanoma cases, approval and acceptance of expensive products by large companies, good prognosis with immunotherapies effective, extending the label of current therapies to new settings in European nations. With the increase in the number of melanoma cases and its poor end-stage prognosis, it has forced the government to take serious initiatives to fight cancer. Moreover, increased investments in R&D are expected along with significant technological advancements in diagnosis and treatment to facilitate market growth during the forecast period.

The growing population and economies of developing countries in Europe are expected to create substantial opportunities for the melanoma therapeutic market. A more effective drug innovation should create substantial opportunities for the European melanoma therapeutics market. The imminent availability of more effective anticancer drugs should offer good prospects for the European melanoma therapeutics market. In addition, the untapped patient population, especially in Europe, would lead to greater acceptance of new treatments in the near future.

One of the latest trends in melanoma therapy is the adoption of combination therapies. The increased demand for personalized medicine and the high potential of developing countries are expected to provide new opportunities for market players in the future during the forecast period.

However, the reluctance of people to undergo treatment and surgery is one of the major constraints to the growth of the European melanoma therapeutics market. Other factors limiting the growth rate of the market are the lack of awareness in some developing regions as well as the high cost associated with the therapy. Difficult factors with economic crisis in many European countries due to covid -19 pandemic will hamper the growth rate of the market. Regulatory issues and standards for developing and bringing new drugs to market is a long and slow process due to these strict laws, which is a significant challenge to the European melanoma therapeutics market.

This research report on the Europe Melanoma Therapeutics Market has been segmented and sub-segmented into the following categories:

By Cancer Stage:

  • Stage 0
  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Cancer Type:

  • Nodular Melanoma
  • Acral Lentiginous Melanoma
  • Superficial Spreading Melanoma
  • Lentigno Maligna Melanoma
  • Amelanotic Melanoma
  • Others

By Diagnosis:

  • Ultrasound
  • Blood Tests
  • Dermatoscopy
  • Sentinel Lymph Node Biopsy
  • X-rays
  • CT Scan

By Treatment: 

  • Early Melanoma
  • Advanced Melanoma-Biological Therapy
  • Targeted Therapy
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Immune Therapy

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the Europe Melanoma Therapeutics market is the third largest market with a global share of 24%. UK is the largest market share holder for the Melanoma Therapeutics market in this region, followed by Germany and France. Europe shows further market expansion due to treatment rates and infiltration into the premium drug market. Increased competition and continuous technological advancements have led to improvements in the product portfolio; therefore, approvals and product development is one of the key development strategies adopted by UK market players in the European melanoma therapeutics market.

The French market is expected to experience comparatively faster growth in terms of revenue over the next 10 years, due to increased investments from leading companies in emerging markets and growing demand for cost-effective therapies. Other notable factors driving the melanoma therapy market in other European countries such as Ireland, Switzerland and Sweden are increased awareness and improvement of healthcare facilities.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the European Melanoma Therapeutics Market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 U.K               

              6.3 Spain                          

              6.4 Germany                   

              6.5 Italy                            

              6.6 France                       

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Melanoma Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Europe Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  3. Europe Stage 0 Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Stage I Market, By Region, From 2021 to 2026 (USD Billion)
  5. Europe Stage II Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Stage III Market, By Region, From 2021 to 2026 (USD Billion)
  7. Europe Stage IV Market, By Region, From 2021 to 2026 (USD Billion)
  8. Europe Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  9. Europe Nodular melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  10. Europe Acral lentiginous melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  11. Europe Superficial spreading melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  12. Europe Lentigno maligna melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  13. Europe Amelanotic melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  14. Europe Other cancers Market, By Region, From 2021 to 2026 (USD Billion)
  15. Europe Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  16. Europe Ultrasound Market, By Region, From 2021 to 2026 (USD Billion)
  17. Europe Blood Tests Market, By Region, From 2021 to 2026 (USD Billion)
  18. Europe Dermatoscopy Market, By Region, From 2021 to 2026 (USD Billion)
  19. Europe Sentinel lymph node biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  20. Europe X-rays Market, By Region, From 2021 to 2026 (USD Billion)
  21. Europe CT Scan Market, By Region, From 2021 to 2026 (USD Billion)
  22. Europe Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  23. Europe early melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  24. Europe advanced melanoma Market, By Region, From 2021 to 2026 (USD Billion)
  25. Europe Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  26. Europe Biological therapy Market, By Region, From 2021 to 2026 (USD Billion)
  27. Europe Targeted therapy Market, By Region, From 2021 to 2026 (USD Billion)
  28. Europe Surgery Market, By Region, From 2021 to 2026 (USD Billion)
  29. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  30. Europe Radiotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  31. Europe Immune therapy Market, By Region, From 2021 to 2026 (USD Billion)
  32. U.K Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  33. U.K Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  34. U.K Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  35. U.K Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  36. U.K Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  37. Spain Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  38. Spain Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  39. Spain Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  40. Spain Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  41. Spain Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  42. Germany Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  43. Germany Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  44. Germany Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  45. Germany Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  46. Germany Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  47. Italy Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  48. Italy Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  49. Italy Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  50. Italy Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  51. Italy Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)
  52. France Melanoma Therapeutics Market, By Cancer stage , From 2021 to 2026 (USD Billion)
  53. France Melanoma Therapeutics Market, By Cancer type , From 2021 to 2026 (USD Billion)
  54. France Melanoma Therapeutics Market, By Diagnosis, From 2021 to 2026 (USD Billion)
  55. France Melanoma Therapeutics Market, By Treatment, From 2021 to 2026 (USD Billion)
  56. France Melanoma Therapeutics Market, By Advanced Melanoma, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample